MBRX NASDAQ
Credit Risk of going bust: higher than 98% of companies Debt: 3.9% of company value Bonds: none of note held by US funds details ▾
Total debt $292K against a stock market value of $7.2M.
Distance to default -0.52 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $145K (short-term plus half of long-term), stock volatility 339.9%; Altman Z'' -43.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Houston, TX 77007
US
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| PICKER DONALD H | A-Award | 250,000 | $0.37 | 2026-10-15 |
| KLEMP WALTER V | M-Exempt | 207,500 | — | 2026-10-15 |
| KLEMP WALTER V | F-InKind | 48,659 | $0.37 | 2026-10-15 |
| KLEMP WALTER V | A-Award | 415,000 | $0.37 | 2026-10-15 |
| KLEMP WALTER V | A-Award | 415,000 | — | 2026-10-15 |